Axogen Inc. (AXGN) shares reached a 52-week high of $50.00 on Tuesday, extending a multi-month rally driven by robust revenue growth in breast reconstruction procedures. The stock last traded just 1% below its peak, reflecting a 222.92% gain over the past 12 months.
The company reported second-quarter 2026 revenue of $69.7 million, a 23% increase from the prior year and ahead of Wall Street’s $67.1 million estimate. Adjusted earnings per share matched expectations at $0.12, though GAAP net loss widened to $1.5 million, or $0.03 per share. Revenue growth was supported by a surge in breast reconstruction procedures, a key driver of the company’s expansion.
Analysts at H.C. Wainwright and Citizens raised their price targets on Axogen. H.C. Wainwright lifted its target to $53 from a prior level, maintaining a Buy rating. Citizens increased its target to $55, keeping its Market Outperform rating. The stock has gained 39% over the past six months and 50% year-to-date, outpacing broader market benchmarks.
Axogen’s market capitalization now stands at approximately $2.67 billion. While the company’s revenue and earnings performance has drawn bullish sentiment, some external analysis suggests the stock may be trading above fair value. InvestingPro noted in its latest assessment that Axogen appeared overvalued relative to its Fair Value estimate, though the platform did not revise its rating.
The company’s next financial update is expected in the third quarter of 2026.
